Çѱ¹ÁöÁú¤ýµ¿¸Æ°æÈÇÐȸ Á¦11Â÷ International Congress on Lipid & Atherosclerosis (ICoLA 2022) 2ÀÏÂ÷ : 2022-09-16±³À°ÀÏÀÚ : 2022-09-16
±³À°Àå¼Ò : ¿©Àǵµ ÄÜ·¡µå È£ÅÚ
±³À°ÁÖÁ¦ :
Á¦11Â÷ International Congress on Lipid & Atherosclerosis (ICoLA 2022) 2ÀÏÂ÷ÁÖÃÖ±â°ü : Çѱ¹ÁöÁú¤ýµ¿¸Æ°æÈÇÐȸ
´ã´çÀÚ : ICoLA2022 »ç¹«±¹
¿¬¶ôó : 02-2285-2507
À̸ÞÀÏ :
secretariat@icola2022.org ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 800¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 22 ½Ã°£ 10ºÐ
¼¼ºÎ¼ö°·á : 140,000¿ø
ºñ°í Àü¹®ÀÇ, ±³¼ö : »çÀüµî·Ï 120,000¿ø / ÇöÀåµî·Ï 140,000¿øÀüÀÓÀÇ, Àü°øÀÇ,Çлý µî : »çÀüµî·Ï 60,000¿ø / 70,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09-16 Room 1 08:00~08:30 Benefits of insulin sensitizer Atherosclerosis & Stroke Jung-hyun Noh(Inje University, Korea)
Åä·Ð 09-16 Room 1 08:30~08:40 Discussion ()
±³À°½Ã°£ 09-16 Room 2 08:00~08:30 Management of uric acid in hypertensive patients: Role of losartan Hack-Lyoung Kim(Seoul National University, Korea)
Åä·Ð 09-16 Room 2 08:30~08:40 Discussion ()
±³À°½Ã°£ 09-16 Room 1,2,3 09:00~09:40 Target discovery & drug development for atherosclerosis in 2020 Sekar Kathiresan(Verve therapeutics, USA)
ÈÞ½Ä 09-16 09:40~09:45 Break ()
±³À°½Ã°£ 09-16 Room 1 09:45~10:05 Novel mechanisms for lipogenesis regulation Gina Lee(University of California Irvine, USA)
±³À°½Ã°£ 09-16 Room 1 10:05~10:25 Local & systemic effect of organ fat deposition Sung Hee Choi(Seoul National University, Korea)
±³À°½Ã°£ 09-16 Room 1 10:25~10:45 Liver & adipose tissue in atherosclerosis Ji Young Lee(University of Connecticut, USA)
Åä·Ð 09-16 Room 1 10:45~11:10 Discussion ()
±³À°½Ã°£ 09-16 Room 2 09:45~10:05 Validation of metabolic targets in adipose tissue for ASCVD Mete Civelek(University of Virginia, USA)
±³À°½Ã°£ 09-16 Room 2 10:05~10:25 Deficiency of myeloid PHD proteins aggravates atherogenesis via macrophage apoptosis & paracrine fibrotic signalling Judith Sluimer(Maastricht University, Netherlands)
±³À°½Ã°£ 09-16 Room 2 10:25~10:45 Recent single cell findings for novel immune & immune-like cell actions in atherosclerosis Jae-Hoon Choi(Hanyang University, Korea)
Åä·Ð 09-16 Room 2 10:45~11:10 Discussion ()
±³À°½Ã°£ 09-16 Room 3 09:45~10:05 What is the role of a polygenic risk score in CV risk assessment? Amit Khera(Verve Therapeutics, USA)
±³À°½Ã°£ 09-16 Room 3 10:05~10:25 Refinement of CV risk in current "very high" & "high" risk groups Hyeon Chang Kim(Yonsei University, Korea)
±³À°½Ã°£ 09-16 Room 3 10:25~10:45 Risk stratification according to age s in new prevention guidelines Kwang-il Kim(Seoul National University, Korea)
Åä·Ð 09-16 Room 3 10:45~11:10 Discussion ()
±³À°½Ã°£ 09-16 Room 4 09:45~10:05 Exercise & inflammation in atherosclerosis Matthias Nahrendorf(Harvard Medical School, USA)
±³À°½Ã°£ 09-16 Room 4 10:05~10:25 Effect of different diets on circulating lipoproteins Frank M. Sacks(Harvard Medical School, USA)
±³À°½Ã°£ 09-16 Room 4 10:25~10:45 Update on heart-healthy diet: studies in the past decade Min-Jeong Shin(Korea University, Korea)
Åä·Ð 09-16 10:45~11:10 Discussion ()
ÈÞ½Ä 09-16 11:15~11:25 Coffee Break ()
±âŸ 09-16 11:25~11:30 Opening Address ()
±³À°½Ã°£ 09-16 Room 1,2,3 11:30~12:00 Recent developments in the treatment of familial hypercholesterolaemia & other familial lipid disorders Brian Tomlinson(Macau University, China)
±³À°½Ã°£ 09-16 Room 1 12:00~12:30 Is combination therapy recommended for high risk ASCVD patients? : When and Why combination therapy is needed Jong-Chan Youn(The Catholic University of Korea, Korea)
Åä·Ð 09-16 Room 1 12:30~12:40 Discussion ()
±³À°½Ã°£ 09-16 Room 2 12:00~12:30 Cutting edge care of Pitavastatin with Ezetimibe combination therapy Junhwa Hong(Eulji University, Korea)
Åä·Ð 09-16 Room 2 12:30~12:40 Discussion ()
±³À°½Ã°£ 09-16 Room 3 12:00~12:30 What are the optimal treatment options of dyslipidemia management for your patients? based on LDL-C lowering continuum So-Yeon Choi(Ajou University, Korea)
Åä·Ð 09-16 Room 3 12:30~12:40 Discussion ()
±³À°½Ã°£ 09-16 Room 1,2,3 12:55~13:35 Senescence & vascular smooth muscle cell plasticity Martin Bennett(University of Cambridge, UK)
±³À°½Ã°£ 09-16 Room 1 13:35~13:55 Current evidence on risk stratifying factors in Koreans Ji Hye Huh(Hallym University, Korea)
±³À°½Ã°£ 09-16 Room 1 13:55~14:15 How much different event risk do Koreans have compared to European descendants? Song Vogue Ahn(Ewha Womans University, Korea)
±³À°½Ã°£ 09-16 Room 1 14:15~14:35 How to of low risk individuals to avoid pharmacotherpy? Hack-Lyoung Kim(Seoul National University, Korea)
Åä·Ð 09-16 Room 1 14:35~15:00 Discussion ()
±³À°½Ã°£ 09-16 Room 2 13:35~13:55 Customized functional food based on big data Jiyoung Kim(Seoul National University, Korea)
±³À°½Ã°£ 09-16 Room 2 13:55~14:15 Customized prevention of metabolic disease in Koreans using omics technology Min Joo Kim(Hannam University, Korea)
±³À°½Ã°£ 09-16 Room 2 14:15~14:35 Healthcare program using digital health device Young In Kim(Noom Inc., Korea)
Åä·Ð 09-16 Room 2 14:35~15:00 Discussion ()
±³À°½Ã°£ 09-16 Room 3 13:35~13:55 Macrophage diversity in inflammation & homeostasis Ichiro Manabe(Chiba University, Japan)
±³À°½Ã°£ 09-16 Room 3 13:55~14:15 Inflammation & hematopoiesis in atherosclerosis Katey Rayner(University of Ottawa, Canada)
±³À°½Ã°£ 09-16 Room 3 14:15~14:35 Immune cell activities in aortic aneurysm Seung-Jun Lee(Yonsei University, Korea)
Åä·Ð 09-16 Room 3 14:35~15:00 Discussion ()
±³À°½Ã°£ 09-16 Room 4 13:35~13:55 Dyslipidaemia - new treatments for ApoC3 and ANGPTL3 Brain Tomlinson(The Chinese University of Hong Kong)
±³À°½Ã°£ 09-16 Room 4 13:55~14:15 New treatment targets beyond LDL-C in dyslipidaemias Alberico Catapano(University of Milan, Italy)
±³À°½Ã°£ 09-16 Room 4 14:15~14:35 Novel Selective PPARa Modulator Pemafibrate for Dyslipidemia Shizuya Yamashita(Rinku General Medical Center, Japan)
Åä·Ð 09-16 14:35~15:00 Discussion ()
ÈÞ½Ä 09-16 15:05~15:15 Break ()
±³À°½Ã°£ 09-16 Room 1 16:15~16:35 Korean evidence on target LDL-C levels Min Kyong Moon(Seoul National University, Korea)
±³À°½Ã°£ 09-16 Room 1 16:35~16:55 Are current Western LDL-C targets for each risk s cost-effective in Koreans? Sang-Hyun Kim(Seoul National University, Korea)
±³À°½Ã°£ 09-16 Room 1 16:55~17:15 When is clinically appropriate to start anti-PCSK9 Abs? Chang-Wook Nam(Keimyung University, Korea)
Åä·Ð 09-16 Room 1 17:15~17:40 Discussion ()
±³À°½Ã°£ 09-16 Room 2 16:20~16:35 Regulation of Macrophage Activation and Differentiation in Atherosclerosis Sung Ho Park(Ulsan National Institute of Science and Technology (UNIST), Korea)
±³À°½Ã°£ 09-16 Room 2 16:35~16:50 Prospect of Artificial Intelligence Based on Electronic Medical Records Hun-Sung Kim(Catholic University of Korea, Korea)
±³À°½Ã°£ 09-16 Room 2 16:50~17:05 Intravital Two-photon Imaging of Dynamic Alteration of Hepatic Lipid Droplets in Fasted and Refed State Philhan Kim(Korea Advanced Institute of Science and Technology (KAIST), Korea)
±³À°½Ã°£ 09-16 Room 2 17:05~17:20 Statin Therapy and the Risk of Osteoporotic Fractures in Patients With Metabolic Syndrome: A Nested Case-Control Study Kyoung Jin Kim(Korea University, Korea)
±³À°½Ã°£ 09-16 Room 2 17:20~17:35 Metabolism and Health Impacts of Dietary Sugars Cholsoon Jang(University of California Irvine, USA)
Åä·Ð 09-16 Room 2 17:35~17:45 Q&A ()
±³À°½Ã°£ 09-16 Room 3 16:15~16:35 Aging as risk factor & therapeutic target in atherosclerosis Sungha Park(Yonsei University, Korea)
±³À°½Ã°£ 09-16 Room 3 16:35~16:55 New target genes & molecules for vascular aging Tohru Minamino(Juntendo University, Japan)
±³À°½Ã°£ 09-16 Room 3 16:55~17:15 What effect do cardiovascular medications & diet have on vascular aging? Kenichi Tsujita(Kumamoto University, Japan)
Åä·Ð 09-16 Room 3 17:15~17:40 Discussion ()
±³À°½Ã°£ 09-16 Room 4 16:15~16:35 Impact of risk factors & medications on COVID-19 outcomes In Sook Kang(Ewha Womens University, Korea)
±³À°½Ã°£ 09-16 Room 4 16:35~16:55 Effect of COVID-19 on dyslipidemia & vascular disease Edward Janus(University of Melbourne, Australia)
±³À°½Ã°£ 09-16 Room 4 16:55~17:15 Benefit & harm of COVID-19 vaccines in ASCVD Ta-Chen Su(National Taiwan University, Taiwan)
Åä·Ð 09-16 Room 4 17:15~17:40 Discussion ()